Kerala Ayurveda Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Kerala Ayurveda's earnings have been declining at an average annual rate of -35.3%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 11.4% per year.
Belangrijke informatie
-35.3%
Groei van de winst
-35.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 11.4% |
| Rendement op eigen vermogen | -0.3% |
| Nettomarge | -0.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Kerala Ayurveda geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,070 | -8 | 368 | 0 |
| 31 Mar 24 | 1,082 | -15 | 432 | 0 |
| 31 Dec 23 | 1,066 | -14 | 413 | 0 |
| 30 Sep 23 | 1,007 | -14 | 395 | 0 |
| 30 Jun 23 | 984 | -4 | 372 | 0 |
| 31 Mar 23 | 936 | -9 | 364 | 0 |
| 31 Dec 22 | 916 | -4 | 357 | 0 |
| 30 Sep 22 | 869 | 28 | 299 | 0 |
| 30 Jun 22 | 788 | 12 | 233 | 0 |
| 31 Mar 22 | 804 | 24 | 282 | 0 |
| 31 Dec 21 | 757 | -14 | 292 | 0 |
| 30 Sep 21 | 726 | -35 | 288 | 0 |
| 30 Jun 21 | 650 | -43 | 239 | 0 |
| 31 Mar 21 | 621 | -48 | 265 | 0 |
| 31 Dec 20 | 645 | -16 | 270 | 0 |
| 30 Sep 20 | 668 | -7 | 272 | 0 |
| 30 Jun 20 | 674 | 25 | 230 | 0 |
| 31 Mar 20 | 768 | 39 | 300 | 0 |
| 31 Dec 19 | 726 | 47 | 272 | 0 |
| 30 Sep 19 | 692 | 47 | 266 | 0 |
| 30 Jun 19 | 610 | 33 | 216 | 0 |
| 31 Mar 19 | 622 | 24 | 249 | 0 |
| 31 Mar 18 | 589 | 28 | 217 | 0 |
| 31 Mar 17 | 504 | 31 | 188 | 0 |
| 31 Mar 16 | 459 | 27 | 168 | 0 |
| 31 Mar 15 | 390 | 24 | 149 | 0 |
| 31 Mar 14 | 349 | 7 | 219 | 0 |
Kwaliteitswinsten: 530163 is currently unprofitable.
Groeiende winstmarge: 530163 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 530163 is unprofitable, and losses have increased over the past 5 years at a rate of 35.3% per year.
Versnelling van de groei: Unable to compare 530163's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 530163 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Rendement op eigen vermogen
Hoge ROE: 530163 has a negative Return on Equity (-0.29%), as it is currently unprofitable.